{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:37:52Z","timestamp":1776134272391,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Initial evidence have shown the short-term efficacy of sTMS in the acute and preventive treatment of migraine. It is unknown whether this treatment approach in the long-term is effective and well tolerated in difficult-to-treat migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective, single centre, open-label, real-world analysis conducted in difficult-to-treat patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM) with and without medication overuse headache (MOH), who were exposed to sTMS therapy. Patients responding to a three-month sTMS treatment, continued the treatment and were assessed again at month 12. The cut-off outcome for treatment continuation was reduction in the monthly moderate to severe headache days (MHD) of at least 30% (headache frequency responders) and\/or a\u2009\u2265\u20094-point reduction in headache disability using the Headache Impact test-6 (HIT-6) (headache disability responders).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred fifty-three patients were included in the analysis (F:M\u2009=\u2009126:27, median age 43, IQR 32.3\u201356.8). At month 3, 93 out of 153 patients (60%) were responders to treatment. Compared to baseline, the median reduction in monthly headache days (MHD) for all patients at month 3 was 5.0\u2009days, from 18.0 (IQR: 12.0\u201326.0) to 13.0\u2009days (IQR: 5.75\u201324.0) (<jats:italic>P<\/jats:italic>\u00a0=\u20090.002,<jats:italic>r<\/jats:italic>\u00a0=\u2009\u2212\u20090.29) and the median reduction in monthly migraine days (MMD) was 4.0\u2009days, from 13.0 (IQR: 8.75\u201322.0) to 9.0 (IQR: 4.0\u201315.25) (<jats:italic>P<\/jats:italic>\u00a0=\u20090.002,<jats:italic>r<\/jats:italic>\u00a0=\u2009\u2212\u20090.29). Sixty-nine out of 153 patients (45%) reported a sustained response to sTMS treatment at month 12. The percentage of patients with MOH was reduced from 52% (<jats:italic>N<\/jats:italic>\u00a0=\u200979\/153) at baseline to 19% (<jats:italic>N<\/jats:italic>\u00a0=\u200929\/153) at month 3, to 8% (<jats:italic>N<\/jats:italic>\u00a0=\u20097\/87) at month 12. There was an overall median 4-point reduction in HIT-6 score, from 66 (IQR: 64\u201369) at baseline to 62 at month 3 (IQR: 56\u201365) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.001,<jats:italic>r<\/jats:italic>\u00a0=\u2009\u2212\u20090.51). A total of 35 mild\/moderate adverse events were reported by 23 patients (15%). One patient stopped sTMS treatment due to scalp sensitivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This open label analysis suggests that sTMS may be an effective, well-tolerated treatment option for the long-term prevention of difficult-to-treat CM and HFEM.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-022-01428-6","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T13:04:03Z","timestamp":1654520643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"J.O.","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Al-Kaisy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Andreou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-4776","authenticated-orcid":false,"given":"G.","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"crossref","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211\u201359. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673617321542","DOI":"10.1016\/S0140-6736(17)32154-2"},{"issue":"1","key":"1428_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"1428_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1468-2982.2003.00494.x","volume":"23","author":"H Rahimtoola","year":"2003","unstructured":"Rahimtoola H, Buurma H, Tijssen C, Leufkens H, Egberts A (2003) Migraine prophylactic medication usage patterns in the Netherlands. Cephalalgia 23(4):293\u2013301","journal-title":"Cephalalgia"},{"issue":"10","key":"1428_CR4","first-page":"1532","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J et al (2017) A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns The Journal of Head Face Pain 57(10):1532\u20131544","journal-title":"A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns The Journal of Head Face Pain"},{"issue":"5","key":"1428_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485","journal-title":"Cephalalgia"},{"key":"1428_CR6","doi-asserted-by":"crossref","first-page":"175628642092711","DOI":"10.1177\/1756286420927119","volume":"13","author":"AP Andreou","year":"2020","unstructured":"Andreou AP, Fuccaro M, Lambru G (2020) The role of erenumab in the treatment of migraine Ther Adv Neurol Disord 13:1756286420927119","journal-title":"The role of erenumab in the treatment of migraine Ther Adv Neurol Disord"},{"issue":"13","key":"1428_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522","journal-title":"Cephalalgia"},{"issue":"1","key":"1428_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61","journal-title":"J Headache Pain"},{"issue":"6","key":"1428_CR9","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037","journal-title":"Cephalalgia"},{"key":"1428_CR10","volume-title":"Neuromodulation in headache and facial pain management: principles","author":"G Lambru","year":"2019","unstructured":"Lambru G, Lanteri-Minet M (2019) Neuromodulation in headache and facial pain management: principles. Springer Nature, Rationale and Clinical Data"},{"issue":"7","key":"1428_CR11","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1177\/0333102417731349","volume":"38","author":"M Trimboli","year":"2018","unstructured":"Trimboli M, Al-Kaisy A, Andreou AP, Murphy M, Lambru G (2018) Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: a real-world experience. Cephalalgia 38(7):1276\u20131285","journal-title":"Cephalalgia"},{"issue":"5","key":"1428_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset X, Bouhassira D, Couturier JA, Alchaar H, Conradi S et al (2020) Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris) 176(5):325\u2013352","journal-title":"Rev Neurol (Paris)"},{"issue":"7","key":"1428_CR13","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/brain\/aww118","volume":"139","author":"AP Andreou","year":"2016","unstructured":"Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J et al (2016) Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139(7):2002\u20132014","journal-title":"Brain"},{"issue":"1","key":"1428_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10194-019-1066-0","volume":"20","author":"AP Andreou","year":"2019","unstructured":"Andreou AP, Edvinsson L (2019) Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 20(1):117","journal-title":"J Headache Pain"},{"key":"1428_CR15","doi-asserted-by":"crossref","unstructured":"Lloyd JO, Chisholm KI, Oehle B, Jones MG, Okine BN, Al-Kaisy A, et al (2020). Cortical mechanisms of single-pulse transcranial magnetic stimulation in migraine. Neurotherapeutics 17(4):1973\u201387. https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00879-6","DOI":"10.1007\/s13311-020-00879-6"},{"issue":"4","key":"1428_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(10)70054-5","volume":"9","author":"RB Lipton","year":"2010","unstructured":"Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK et al (2010) Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology 9(4):373\u2013380","journal-title":"Lancet Neurology"},{"issue":"6","key":"1428_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0333102418762525","volume":"38","author":"AJ Starling","year":"2018","unstructured":"Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS et al (2018) A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE study). Cephalalgia 38(6):1038\u20131048","journal-title":"Cephalalgia"},{"key":"1428_CR18","doi-asserted-by":"crossref","unstructured":"Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, et al (2015). Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain 16(1):1-8. https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-015-0535-3","DOI":"10.1186\/s10194-015-0535-3"},{"key":"1428_CR19","unstructured":"Powell J. (2014). Transcranial magnetic stimulation for treating and preventing migraine: Interventional procedures guidance [IPG477].https:\/\/www.nice.org.uk\/guidance\/ipg477"},{"key":"1428_CR20","unstructured":"NICE (2014) Clinical audit tool: Transcranial magnetic stimulation for treating and preventing migraine National Institute for Health and Care Excellence [cited 2020; Available from: http:\/\/guidance.nice.org.uk\/IPG477"},{"key":"1428_CR21","unstructured":"Ltd BC (2022) editorial policies biomedcentral [Available from: https:\/\/www.biomedcentral.com\/getpublished\/editorial-policies#duplicate+publication"},{"key":"1428_CR22","unstructured":"MRC, HRA (2017) Is my study research? [Available from: http:\/\/www.hra-decisiontools.org.uk\/research\/"},{"issue":"5","key":"1428_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","volume":"17","author":"IHS","year":"2018","unstructured":"IHS (2018) International classification of headache disorders. Lancet Neurol 17(5):396\u2013397","journal-title":"Lancet Neurol"},{"issue":"8","key":"1428_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"A Andreou","year":"2018","unstructured":"Andreou A, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S et al (2018) Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal. Eur J Neurol 25(8):1069\u20131e83","journal-title":"Eur J Neurol"},{"key":"1428_CR25","unstructured":"National Institute for Health Care Excellence. (2012). Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance [TA260]. Published date. https:\/\/www.nice.org.uk\/guidance\/ta260"},{"issue":"4","key":"1428_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0333102419877171","volume":"40","author":"MA Chalmer","year":"2020","unstructured":"Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J (2020) Proposed new diagnostic criteria for chronic migraine. Cephalalgia 40(4):399\u2013406","journal-title":"Cephalalgia"},{"issue":"1","key":"1428_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P et al (2020) European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain 21(1):1\u201312","journal-title":"J Headache Pain"},{"issue":"1","key":"1428_CR28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1186\/s40064-016-2924-8","volume":"5","author":"B Br\u00fcggenj\u00fcrgen","year":"2016","unstructured":"Br\u00fcggenj\u00fcrgen B, Baker T, Bhogal R, Ahmed F (2016) Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting. SpringerPlus 5(1):1249","journal-title":"SpringerPlus"},{"issue":"6","key":"1428_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"key":"1428_CR30","doi-asserted-by":"crossref","unstructured":"Winner P, Singh RH, Cohen J, Yang R, Yeung P, Campos VR. (2019). Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication. Neurology 92(15): P2.10-001. https:\/\/n.neurology.org\/content\/92\/15_Supplement\/P2.10-001.abstract","DOI":"10.1212\/WNL.92.15_supplement.P2.10-001"},{"issue":"1","key":"1428_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL, Aurora SK, L\u00e1inez MJA (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19(1):121","journal-title":"J Headache Pain"},{"issue":"1","key":"1428_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Gg L, Nie H, Yy F, Gy G et al (2020) Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine \u2013 an updated systematic review and meta-analysis. BMC Neurology 20(1):57","journal-title":"BMC Neurology"},{"issue":"1","key":"1428_CR33","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.36076\/2017.1.E151","volume":"20","author":"D Rodrigo","year":"2017","unstructured":"Rodrigo D, Acin P, Bermejo P (2017) Occipital nerve stimulation for refractory chronic migraine: results of a long-term prospective study. Pain Phys 20(1):E151\u2013E1E9","journal-title":"Pain Phys"},{"issue":"1","key":"1428_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-016-0659-0","volume":"17","author":"S Miller","year":"2016","unstructured":"Miller S, Watkins L, Matharu M (2016) Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients. J Headache Pain 17(1):68","journal-title":"J Headache Pain"},{"issue":"7","key":"1428_CR35","first-page":"1151","volume":"46","author":"A Rapoport","year":"2006","unstructured":"Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials headache: the journal of head and face. Pain 46(7):1151\u20131160","journal-title":"Pain"},{"issue":"5","key":"1428_CR36","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"issue":"5","key":"1428_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener H, Dodick D, Silberstein S, Lipton R et al (2018) International headache society clinical trials standing committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832","journal-title":"Cephalalgia"},{"issue":"1","key":"1428_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-020-00221-w","volume":"4","author":"JH Ford","year":"2020","unstructured":"Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W et al (2020) A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient-Reported Outcomes 4(1):1\u201311","journal-title":"J Patient-Reported Outcomes"},{"key":"1428_CR39","first-page":"215013272095993","volume":"11","author":"AM Blumenfeld","year":"2020","unstructured":"Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A et al (2020) Patient-reported outcomes from a 1-year, real-world, head-to-head comparison of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine journal of primary Care & Community. Health 11:2150132720959936","journal-title":"Health"},{"issue":"19","key":"1428_CR40","doi-asserted-by":"publisher","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","volume":"92","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF et al (2019) Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology 92(19):e2250\u2013e2e60","journal-title":"Neurology"},{"issue":"1","key":"1428_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0333102413497599","volume":"34","author":"AF Smelt","year":"2014","unstructured":"Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW (2014) What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia 34(1):29\u201336","journal-title":"Cephalalgia"},{"issue":"9","key":"1428_CR42","first-page":"2003","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth R, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the headache impact test (HIT-6) Total and item-specific scores in chronic migraine headache: the journal of head and face. Pain 60(9):2003\u20132013","journal-title":"Pain"},{"issue":"7","key":"1428_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"H Diener","year":"2010","unstructured":"Diener H, Dodick DW, Aurora S, Turkel C, DeGryse R et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814","journal-title":"Cephalalgia"},{"issue":"7","key":"1428_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"H-C Diener","year":"2007","unstructured":"Diener H-C, Bussone G, Oene JV, Lahaye M, Schwalen S et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, Double-Blind, Placebo-Controlled Study. Cephalalgia 27(7):814\u2013823","journal-title":"Cephalalgia"},{"issue":"22","key":"1428_CR45","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"24","key":"1428_CR46","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2e21","journal-title":"Neurology"},{"issue":"13","key":"1428_CR47","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1e77","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01428-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T14:22:54Z","timestamp":1727360574000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01428-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Audit under current national guidelines does not require prior research ethics committee review (http:\/\/\/).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JL reports no disclosure. B.H. reports no disclosure. M.M. reports no disclosure. AAK investigator with Nevro, Boston Scientific, Abbott and Medtronic and has stock in Micron LLC. A.P.A received speaker honoraria and funding for travel from Allergan, Eli Lilly and eNeura, honoraria for participation in advisory boards sponsored by Allergan and Eli Lilly, sponsorship for educational purposes from eNeura, Allergan, Autonomic Technologies and Novartis, and an equipment grant from eNeura. G.L. has received speaker honoraria, funding for travel and has received honoraria for participation in advisory boards sponsored by Allergan, Novartis, Eli Lilly, TEVA and Lundbeck. He has received speaker honoraria, funding for travel from electroCore, Nevro Corp. and Autonomic Technologies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}